Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program

Direct Payment

$37,499.00

Development of novel therapeutics in ER negative, HER-2 negative early stage breast cancer, based upon the identification and validation of molecular pathways associated with early relapse

EF 2008-09

Résumé
Breast cancer is the most common cancer and second leading cause of cancer death in Canadian women. Although there are effective treatments available, many breast cancer survivors will still experience a relapse. It would therefore be useful to not only study which genetic material alterations may cause an earlier relapse, but also to investigate new drugs to target these alterations, in order to improve cancer survival. Many different cutting-edge molecular techniques are being used in breast cancer research today. These include gene microarray technology (studying which genes are turned on and which are turned off), and using different molecules to target the genetic material alterations in cancer cells. Previously, I have identified over ten genes which are associated with earlier relapse in a difficult to treat subtype of breast cancer cells. I will attempt to first verify that these genes are truly associated with earlier relapse in this subtype of breast cancer, using different molecular tools including looking at protein levels. Once these genetic alterations are verified, I will then use different molecules to try to affect these alterations. I also plan to study new drugs targeted towards these genetic material alterations, to see whether they have any effects on the growth and other properties of the cancer cells. It is hoped that by studying the changes in genetic material and protein levels within different breast cancer cells and studying new drugs systemically, that this will affect the growth of these cancer cells. If found, these new drugs may hold potential for further testing in human subjects with breast cancer. Ultimately, these drugs may one day be used in the clinic in order to decrease the chances of a woman's breast cancer coming back, thereby resulting in improved survival and outcomes.
Programme
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
178343
Name
Tsang Roger
Region
California
Country
United States of America
Orgtype
Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Development of novel therapeutics in ER negative, HER-2 negative early stage breast cancer, based upon the identification and validation of molecular pathways associated with early relapse
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$37,499
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Breast Cancer; Dna Microarray; Novel Therapeutics; Small Interfering Rna (Sirna); Small-Molecule Inhibitors; Targeted Chemotherapeutics; Translational Research; Triple-Negative Breast Cancer
Abstract
Breast cancer is the most common cancer and second leading cause of cancer death in Canadian women. Although there are effective treatments available, many breast cancer survivors will still experience a relapse. It would therefore be useful to not only study which genetic material alterations may cause an earlier relapse, but also to investigate new drugs to target these alterations, in order to improve cancer survival. Many different cutting-edge molecular techniques are being used in breast cancer research today. These include gene microarray technology (studying which genes are turned on and which are turned off), and using different molecules to target the genetic material alterations in cancer cells. Previously, I have identified over ten genes which are associated with earlier relapse in a difficult to treat subtype of breast cancer cells. I will attempt to first verify that these genes are truly associated with earlier relapse in this subtype of breast cancer, using different molecular tools including looking at protein levels. Once these genetic alterations are verified, I will then use different molecules to try to affect these alterations. I also plan to study new drugs targeted towards these genetic material alterations, to see whether they have any effects on the growth and other properties of the cancer cells. It is hoped that by studying the changes in genetic material and protein levels within different breast cancer cells and studying new drugs systemically, that this will affect the growth of these cancer cells. If found, these new drugs may hold potential for further testing in human subjects with breast cancer. Ultimately, these drugs may one day be used in the clinic in order to decrease the chances of a woman's breast cancer coming back, thereby resulting in improved survival and outcomes.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tsang, Roger
Approvedterm
1 an 0 mois
Cihrcontribution2
Patient Oriented Research~ $37,499~ $0~